Diagnosis and Therapeutic Management of Extra-Intestinal Manifestations of Inflammatory Bowel Disease

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Drugs

• Publication date

  2012-12-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.2165/11638120-000000000-00000PMID 23181971
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Neurologic Complications in Patients with Inflammatory Bowel Disease: Increasing Relevance in the Era of Biologics

  2013influential reference
• Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

  2012influential reference
• Skin Manifestations of Inflammatory Bowel Disease

  2012cited by this paper
• High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia

  2012influential reference
• Duration and severity of primary sclerosing cholangitis is not associated with risk of neoplastic changes in the colon in patients with ulcerative colitis.

  2012cited by this paper
• Renal manifestations and complications of inflammatory bowel disease

  2011cited by this paper
• Thoracic manifestations of inflammatory bowel disease.

  2011influential reference
• What's Hot in the Red Journal This Month

  2011influential reference
• Meta‐analysis: ursodeoxycholic acid for primary sclerosing cholangitis

  2011influential reference
• Influence of ileal pouch anal anastomosis on bone loss in ulcerative colitis patients.

  2011cited by this paper
• Bone, Inflammation, and Inflammatory Bowel Disease

  2011cited by this paper
• Extraintestinal manifestations of inflammatory bowel disease.

  2011cited by this paper
• Extraintestinal manifestations of inflammatory bowel disease: Epidemiology, diagnosis, and management

  2010influential reference
• Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease

  2010influential reference
• Pulmonary involvement in inflammatory bowel disease.

  2010cited by this paper
• Diagnosis and management of primary sclerosing cholangitis

  2010influential reference
• High‐dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis

  2009cited by this paper
• Development of extraintestinal manifestations in pediatric patients with inflammatory bowel disease

  2009influential reference
• Risk Factors for Low Bone Mass in Patients With Ulcerative Colitis Following Ileal Pouch-Anal Anastomosis

  2009cited by this paper
• Peripheral neuropathy in inflammatory bowel disease patients: A prospective cohort study

  2009cited by this paper
• Use of Infliximab in Particular Clinical Settings: Management Based on Current Evidence

  2009cited by this paper
• Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis.

  2009cited by this paper
• Inflammatory bowel disease: complications and extraintestinal manifestations.

  2009influential reference
• Risk of Arterial Thrombotic Events in Inflammatory Bowel Disease

  2009influential reference
• Rising Prevalence of Venous Thromboembolism and Its Impact on Mortality Among Hospitalized Inflammatory Bowel Disease Patients

  2008influential reference
• Extraintestinal manifestations of inflammatory bowel disease

  2008cited by this paper
• Extraintestinal manifestations of inflammatory bowel disease.

  2008cited by this paper
• Peripheral neuropathy and neurological disorders in an unselected Brazilian population‐based cohort of IBD patients

  2008influential reference
• Skin manifestations of inflammatory bowel disease.

  2008cited by this paper
• The Etiology of Steroid Cataract

  2007cited by this paper
• High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis

  2007cited by this paper
• Thoracic manifestations of inflammatory bowel disease.

  2007cited by this paper
• Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents.

  2007cited by this paper
• Hepatitis B and C virus infections and anti‐tumor necrosis factor‐α therapy: Guidelines for clinical approach

  2006cited by this paper
• Do Guidelines Matter? Implementation of the ACG and AGA Osteoporosis Screening Guidelines in Inflammatory Bowel Disease (IBD) Patients Who Meet the Guidelines' Criteria

  2006cited by this paper
• The effect of anti-TNF-alpha therapy on spinal bone mineral density in patients with Crohn's disease.

  2006cited by this paper
• A Double-Blind Placebo-Controlled Study of the Effects of the Bisphosphonate Risedronate on Bone Mass in Patients with Inflammatory Bowel Disease

  2006cited by this paper
• Primary Sclerosing Cholangitis, Inflammatory Bowel Disease, and Colon Cancer

  2006influential reference
• American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease.

  2006cited by this paper
• [Extraintestinal manifestations in inflammatory bowel disease: differences between Crohn's disease and ulcerative colitis].

  2006influential reference
• Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.

  2006cited by this paper
• Inflammatory bowel disease and the lung: is there a link between surgery and bronchiectasis?

  2006cited by this paper
• The Effect of Anti‐TNF‐α Therapy on Spinal Bone Mineral Density in Patients with Crohn's Disease

  2006cited by this paper
• Extraintestinal manifestations and complications in inflammatory bowel diseases.

  2006influential reference
• Extraintestinal manifestations of inflammatory bowel disease.

  2005influential reference
• Combining information obtained from magnetic resonance imaging and conventional radiographs to detect sacroiliitis in patients with recent onset inflammatory back pain

  2005cited by this paper
• Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial

  2005influential reference
• The effect of infliximab on extraintestinal manifestations of Crohn’s disease

  2005cited by this paper
• Topical Tacrolimus Therapy for Pyoderma Gangrenosum

  2005cited by this paper
• The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study.

  2005influential reference
• Manifestaciones extraintestinales en la enfermedad inflamatoria intestinal: diferencias entre la enfermedad de Crohn y la colitis ulcerosa

  2005cited by this paper
• Crohn's Disease Associated with Sweet's Syndrome and Sjögren's Syndrome Treated with Infliximab

  2005cited by this paper
• [Extraintestinal manifestations in inflammatory bowel disease: differences between Crohn's disease and ulcerative colitis].

  2005cited by this paper
• A case–control study of bronchial asthma associated with ulcerative colitis: role of airway microvascular permeability

  2005cited by this paper
• Increased risk for demyelinating diseases in patients with inflammatory bowel disease.

  2005cited by this paper
• Peripheral neuropathy in patients with inflammatory bowel disease.

  2005cited by this paper
• Extraintestinal manifestations in inflammatory bowel disease.

  2005cited by this paper
• PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis

  2004influential reference
• Tumor necrosis factor α blockade with infliximab for refractory uveitis and scleritis

  2004cited by this paper
• Rare extraintestinal manifestations of inflammatory bowel disease.

  2004influential reference
• Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis.

  2004cited by this paper
• Rofecoxib and early relapse of inflammatory bowel disease: an open‐label trial

  2004cited by this paper
• Management of extraintestinal manifestations and other complications of inflammatory bowel disease

  2004influential reference
• Infliximab in spondyloarthropathy associated with Crohn’s disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations

  2004cited by this paper
• Autoimmune Disorders and Extraintestinal Manifestations in First-degree Familial and Sporadic Inflammatory Bowel Disease: A Case–Control Study

  2004influential reference
• Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism?

  2004cited by this paper
• Ocular Manifestations of Inflammatory Bowel Disease

  2004cited by this paper
• Bone density improves with disease remission in patients with inflammatory bowel disease

  2003influential reference
• Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease

  2003cited by this paper
• A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease

  2003cited by this paper
• An open‐label trial of the selective cyclo‐oxygenase‐2 inhibitor, rofecoxib, in inflammatory bowel disease‐associated peripheral arthritis and arthralgia

  2003cited by this paper
• Sonographic Prevalence of Liver Steatosis and Biliary Tract Stones in Patients with Inflammatory Bowel Disease: Study of 511 Subjects at a Single Center

  2003influential reference
• Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes.

  2002influential reference
• Treatment of acute uveitis associated with Crohn's disease and sacroileitis with infliximab

  2002cited by this paper
• Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial.

  2002cited by this paper
• Hepatic and extrahepatic malignancies in primary sclerosing cholangitis.

  2002cited by this paper
• Alterations in pulmonary function in inflammatory bowel disease are frequent and persist during remission

  2002influential reference
• Extraintestinal manifestations of inflammatory bowel disease.

  2002cited by this paper
• Risk factors for developing renal stones in inflammatory bowel disease

  2002influential reference
• Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis.

  2002cited by this paper
• Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease

  2002cited by this paper
• Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's disease

  2002cited by this paper
• Hepatitis B and C Virus Infection in Crohn's Disease

  2001cited by this paper
• The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study

  2001influential reference
• Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis.

  2001influential reference
• Secondary Amyloidosis in Inflammatory Bowel Disease: A Study of 18 Patients Admitted to Rikshospitalet University Hospital, Oslo, from 1962 to 1998

  2001influential reference
• Sarcoidosis and inflammatory bowel disease.

  2001influential reference
• Muscoloskeletal manifestations in inflammatory bowel disease.

  2001cited by this paper
• Variant forms of cholestatic diseases involving small bile ducts in adults

  2000cited by this paper
• Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease.

  2000cited by this paper
• The lung in inflammatory bowel disease.

  2000influential reference
• The Incidence of Fracture among Patients with Inflammatory Bowel Disease: A Population-Based Cohort Study

  2000cited by this paper
• Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease.

  2000influential reference
• High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis

  2000cited by this paper
• [Primary sclerosing cholangitis].

  2000influential reference
• Primary sclerosing cholangitis

  1999cited by this paper
• Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study.

  1999cited by this paper
• Cyclosporine neurotoxicity: a review

  1999cited by this paper
• Renal and Urologic Complications of Inflammatory Bowel Disease

  1998influential reference
• Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history

  1998cited by this paper

• The Knowledge, Attitude, and Perception (KAP) of Healthcare Professionals in Pediatric Settings Toward Oral Manifestations of Inflammatory Bowel Disease (IBD): A Survey-Based Cross-Sectional Study.

  2026cites this paper
• Extra intestinal manifestations may increase the risk of synchronous and metachronous development of other extraintestinal manifestations in patients with Crohn’s disease

  2025cites this paper
• Metabolic musculoskeletal disorders in patients with inflammatory bowel disease

  2025cites this paper
• The causal impact of genetically predicted inflammatory bowel disease on extraintestinal manifestations: a mendelian randomization study

  2025cites this paper
• Extraintestinal manifestations in pediatric inflammatory bowel disease (a single-center experience from the Middle East)

  2025cites this paper
• Oral Extraintestinal Manifestations of Inflammatory Bowel Disease: The Temporal Relationship Between Oral and Intestinal Symptoms

  2025cites this paper
• Anti–Tumor Necrosis Factor Therapy and Risk of Kidney Function Decline and Mortality in Inflammatory Bowel Disease

  2024cites this paper
• 18F-FDG-PET and other imaging modalities in the diagnosis and management of inflammatory bowel disease.

  2024cites this paper
• T cell trafficking in human chronic inflammatory diseases

  2024cites this paper
• Ophthalmological Manifestations in Inflammatory Bowel Diseases: Keep an Eye on It

  2024cites this paper
• Ocular Manifestations of Inflammatory Bowel Disease

  2023cites this paper
• Ulcerative colitis and pyoderma gangrenosum presentation of a case and brief literature review

  2023cites this paper
• Personalized Treatment for Crohn’s Disease: Current Approaches and Future Directions

  2023cites this paper
• Pathogenesis, assessment, and management of bone loss in axial spondyloarthritis.

  2023cites this paper
• Current insights on the roles of gut microbiota in inflammatory bowel disease-associated extra-intestinal manifestations: pathophysiology and therapeutic targets

  2023cites this paper
• Extraintestinal Manifestations of Inflammatory Bowel Disease Are Associated With Increased Biologic Cycling

  2023cites this paper
• Biofilm's Impact on Inflammatory Bowel Diseases

  2023cites this paper
• Prevalence of Extraintestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.

  2023cites this paper
• Renal manifestations in inflammatory bowel disease: a systematic review

  2022cites this paper
• Concomitant Guillain–Barré Syndrome in a young Sri Lankan male with severe ulcerative colitis

  2022cites this paper
• COVID‐19 and inflammatory bowel disease crosstalk: From emerging association to clinical proposal

  2022cites this paper
• Complications of Ulcerative Colitis in Children

  2022cites this paper
• The Risk of Later Diagnosis of Inflammatory Bowel Disease in Patients With Dermatological Disorders Associated With Inflammatory Bowel Disease.

  2021cites this paper
• Extra-Intestinal Features of Crohn’s Disease

  2021cites this paper
• Extra-Intestinal Manifestations of Inflammatory Bowel Disease

  2021cites this paper
• Symptoms of central sensitization in patients with inflammatory bowel diseases: a case-control study examining the role of musculoskeletal pain and psychological factors.

  2021cites this paper
• Expression of inflammatory mediators in biofilm samples and clinical association in inflammatory bowel disease patients—a preliminary study

  2021cites this paper
• Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management.

  2021cites this paper
• Prevalence and Real-World Management of Vedolizumab Associated Enthesitis in Successfully Treated IBD Patients.

  2021cites this paper
• Site-specific targeted drug delivery systems for the treatment of inflammatory bowel disease.

  2020cites this paper
• Dermatological Manifestations in Pediatric Inflammatory Bowel Disease

  2020cites this paper
• Oral Manifestations of Inflammatory Bowel Disease and the Role of Non-Invasive Surrogate Markers of Disease Activity

  2020cites this paper
• Respiratory Tract Manifestations of Inflammatory Bowel Disease.

  2020cites this paper
• Distributions and Power of Optimal Signal-Detection Statistics in Finite Case

  2020cites this paper
• Factors Associated with the Presence of Extraintestinal Manifestations in Patients with Ulcerative Colitis in a Latin American Country

  2020cites this paper
• Therapeutic Dimensions of Bisphosphonates: A Clinical Update

  2020cites this paper
• Symptoms of central sensitization in patients with inflammatory bowel diseases: a case-control study examining the role of musculoskeletal pain and psychological factors

  2020cites this paper
• Extra-intestinal Manifestations in Inflammatory Bowel Disease: Diagnosis and Management

  2019cites this paper
• Celiac disease-specific and inflammatory bowel disease-related antibodies in patients with recurrent aphthous stomatitis.

  2019cites this paper
• Occurrence of skin manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study

  2019cites this paper
• Extraintestinal manifestations in inflammatory bowel disease – epidemiology, genetics, and pathogenesis

  2019cites this paper
• Musculoskeletal Pain in Individuals With Inflammatory Bowel Disease Reflects Three Distinct Profiles

  2019cites this paper
• The difference in extraintestinal manifestations of inflammatory bowel disease for children and adults.

  2019cites this paper
• Primary sclerosing cholangitis and inflammatory bowel disease: Intestine–liver interrelation

  2019cites this paper
• Primary sclerosing cholangitis and inflammatory bowel disease: Intestine-liver interrelation.

  2019cites this paper
• Extraintestinal Manifestations of Inflammatory Bowel Disease: Epidemiology, Etiopathogenesis, and Management

  2019cites this paper
• Central hypersensitivity - A model for persistent musculoskeletal pain in inflammatory bowel diseases.

  2019cites this paper
• Clinical outcomes and risk factors of secondary extraintestinal manifestation in ulcerative colitis: results of a multicenter and long-term follow-up retrospective study

  2019cites this paper
• Inflammatory bowel disease: Looking beyond the tract

  2019cites this paper
• Primary sclerosing cholangitis associated with inflammatory bowel disease

  2019cites this paper
• Deficient Resident Memory T Cell and CD8 T Cell Response to Commensals in Inflammatory Bowel Disease

  2019cites this paper
• Extraintestinal Manifestations of Inflammatory Bowel Disease

  2019cites this paper
• COMMENSALS IN INFLAMMATORY BOWEL DISEASE

  2019cites this paper
• Profile of musculoskeletal pain in patients with inflammatory bowel disease: a study protocol for assessing the multidimensional experience of self-reported pain

  2018cites this paper
• Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease.

  2018cites this paper
• Low Rates of Dermatologic Care and Skin Cancer Screening Among Inflammatory Bowel Disease Patients

  2018cites this paper
• Management of Crohn's Disease and Complications in Patients With Ostomies.

  2018cites this paper
• Bowel Disease Patients with Arthritis and Arthralgia Phenotypic Features and Longterm Outcomes of Pediatric Inflammatory

  2017cites this paper
• Hidradenitis suppurativa in Crohn's disease during adalimumab therapy: a paradox?

  2017cites this paper
• Crosstalk between the gut and the liver via susceptibility loci: Novel advances in inflammatory bowel disease and autoimmune liver disease.

  2017cites this paper
• Distributions and Statistical Power of Optimal Signal-Detection Methods In Finite Cases

  2017cites this paper
• Enfermedad inflamatoria intestinal: abordaje conjunto digestivo-dermatológico

  2017cites this paper
• Inflammatory Bowel Disease: Joint Management in Gastroenterology and Dermatology.

  2017cites this paper
• USING REAL-WOLRD HEALTHCARE DATA TO DEFINE AND PREVENT COMPLICATIONS IN INFLAMMATORY BOWEL DISEASE

  2017cites this paper
• Inflammatory Bowel Disease: Joint Management in Gastroenterology and Dermatology

  2017cites this paper
• Phenotypic Features and Longterm Outcomes of Pediatric Inflammatory Bowel Disease Patients with Arthritis and Arthralgia

  2017cites this paper
• Skin Manifestations of Inflammatory Bowel Disease

  2017cites this paper
• Oral manifestations of inflammatory bowel disease.

  2017cites this paper
• Lung injury as an extra-intestinal manifestation of inflammatory bowel disease

  2016cites this paper
• Erfassung der Lebersteifigkeit mittels der "Acoustic Radiation Force Impulse" Bildgebung bei Patienten mit chronisch-entzündlichen Darmerkrankungen

  2016cites this paper
• Extraintestinal Findings in Crohn’s Disease Patients

  2016cites this paper
• Oral Pathology unmasking Gastrointestinal Disease

  2016cites this paper
• Psoriasis and inflammatory bowel disease: links and risks

  2016cites this paper
• Rheumatic manifestations in inflammatory bowel diseases: a link between GI and rheumatology

  2016cites this paper
• Optimizing anti-TNF therapy in inflammatory bowel disease

  2016influential citation
• Is it bowel-associated dermatosis-arthritis syndrome induced by small intestinal bacteria overgrowth?

  2016cites this paper
• Complete resolution of non‐necrotizing lung granuloma and pyoderma gangrenosum after restorative proctocolectomy in a woman with severe ulcerative colitis and cytomegalovirus infection

  2016cites this paper
• Manifestaciones extraintestinales en la enfermedad inflamatoria intestinal

  2016cites this paper
• The relationship between the immune system and oral manifestations of inflammatory bowel disease: a review

  2016cites this paper
• Pulmonary manifestations of inflammatory bowel disease

  2015cites this paper
• Extraintestinal Manifestations of Inflammatory Bowel Disease

  2015influential citation
• Cutaneous Manifestations of Crohn Disease.

  2015cites this paper
• A Clinical Review on The Holism of Ophthalmology - The Associations Between Systemic Diseases and Ocular Conditions

  2015cites this paper
• Serum Concentration of Anti-TNF Antibodies, Adverse Effects and Quality of Life in Patients with Inflammatory Bowel Disease in Remission on Maintenance Treatment.

  2015influential citation
• Extraintestinal Manifestations Associated with Inflammatory Bowel Disease.

  2015influential citation
• The genetics of pyoderma gangrenosum and implications for treatment: a systematic review

  2015cites this paper
• Review article: non‐malignant oral manifestations in inflammatory bowel diseases

  2015cites this paper
• Febrile pleuropericarditis, a potentially life-threatening adverse event of balsalazide – case report and literature review of the side effects of 5-aminosalicylates

  2014cites this paper
• Musculoskeletal manifestations in inflammatory bowel disease: a revisit in search of immunopathophysiological mechanisms.

  2014cites this paper
• Hepatobiliary manifestations of ulcerative colitis: an example of gut–liver crosstalk

  2014cites this paper
• Biologics for extraintestinal manifestations of IBD.

  2014cites this paper
• Manifestaciones oculares de la enfermedad inflamatoria intestinal

  2014cites this paper
• Jacobs Journal of Clinical Case Reports Acute Eosinophilic Pneumonia in a Patient with Inflammatory Bowel Disease

  2014cites this paper
• Adalimumab treatment for hidradenitis suppurativa associated with Crohn's disease.

  2014cites this paper
• Treatment options for extra-intestinal manifestations of inflammatory bowel disease vary, but remain limited for some

  2013influential citation
• Oral manifestation in inflammatory bowel disease: a review.

  2013cites this paper
• Treatment options for extra-intestinal manifestations of inflammatory bowel disease vary, but remain limited for some

  2013cites this paper
• The application of RNAi-based treatments for inflammatory bowel disease

  2013cites this paper
• Extraintestinal manifestations and complications in IBD

  2013cites this paper
• Extra-Intestinal Crohn's Disease and Pyoderma Gangrenosum as a Diagnostic Dilemma: Case Report

  2013cites this paper